단순 포진 바이러스 백신의 개발 및 도전
Challenge of Developing a Herpes Simplex Virus Vaccine
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as human herpes virus 1 and 2 (HHV-1 and HHV-2), are two members of the herpes virus family, herpes viridae, which infect humans. Both HSV-1 (which produces most cold sores) and HSV-2 (which produces most genital herpes) are ubiquitous and contagious. They can be spread when an infected person is producing and shedding the virus. Herpes Simplex can be spread through contact with saliva, such as sharing drinks. HSV-2 is one of the most prevalent sexually transmitted infections worldwide. In addition to recurrent genital ulcers, HSV-2 causes neonatal herpes, and is associated with a 3-fold increased risk for HIV acquisition. Many HSV-2 vaccines have been studied in animal models, however, few have reached clinical trials, and those that have been tested in humans were not consistently effective. Here, I review HSV-2 pathogenesis, with a focus on novel understanding of mucosal immunobiology of HSV-2, and vaccine efforts to date, in an attempt to stimulate thinking about future directions for development of effective prophylactic and therapeutic HSV-2 vaccines.
Abstract
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as human herpes virus 1 and 2 (HHV-1 and HHV-2), are two members of the herpes virus family, herpes viridae, which infect humans. Both HSV-1 (which produces most cold sores) and HSV-2 (which produces most genital herpes) are ubiquitous and contagious. They can be spread when an infected person is producing and shedding the virus. Herpes Simplex can be spread through contact with saliva, such as sharing drinks. HSV-2 is one of the most prevalent sexually transmitted infections worldwide. In addition to recurrent genital ulcers, HSV-2 causes neonatal herpes, and is associated with a 3-fold increased risk for HIV acquisition. Many HSV-2 vaccines have been studied in animal models, however, few have reached clinical trials, and those that have been tested in humans were not consistently effective. Here, I review HSV-2 pathogenesis, with a focus on novel understanding of mucosal immunobiology of HSV-2, and vaccine efforts to date, in an attempt to stimulate thinking about future directions for development of effective prophylactic and therapeutic HSV-2 vaccines.
참고문헌 (26)
- Looker KJ, "An estimate of the global prevalence and incidence of herpes simplex virus type 2infection", Bull World Health Organ, 86, pp.805~812 (2008)
- Freeman EE, "Herpes simplex virus 2 infection increases HIV acquisition in men and women : systematic review and meta-analysis of longitudinal studies", AIDS, 20, pp.73~83 (2006)
- Nagot N, "Reduction of HIV-1RNA levels with therapy to suppress herpes simplex virus", N Engl J Med, 356, pp.790~799 (2007)
- Johnston C, "HSV-2 : in pursuit of a vaccine", J Clin Invest, 121, pp.4600~4609 (2011)
- Koelle DM, "Recent progress in herpes simplex virus immunobiology and vaccine research", Clin Microbiol Rev, 16, pp.96~113 (2003)
- Dervillez X, "Future of an"asymptomatic"T-cell epitope-based therapeutic herpes simplex vaccine", Future Virol, 7, pp.371~378 (2012)
- Corey L, "An update on short-course episodic and prevention therapies for herpes genitalis", Herpes, 14(Suppl 1), pp.5A~11A (2007)
- Field HJ, "Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus", J Gen Virol, 49, pp.115~124 (1980)
- Semenova TB, "Properties of herpes simplex virus strains isolated from patients with recurrent cutaneous herpes", Vopr Virusol, 30, pp.93~96 (1985)
- Dundarov S, "Characterization of herpes simplex virus strains isolated from patients with various diseases", Arch Virol, 63, pp.115~121 (1980)
- Skinner GR, "Prevention of herpes genitalis by the 'Bulgarian' vaccine F.HSV-2V(PRK):preliminary clinical evidence", Croat Med J, 41, pp.378~383 (2000)
- Wachsman M, "A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs", Vaccine, 19, pp.1879~1890 (2001)
- Courreges MC, "Preparation of apoptotic tumor cells with replicationincompetent HSV augments the efficacy of dendritic cell vaccines", Cancer Gene Ther, 13, pp.182~193 (2006)
- Watanabe D, "Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector", Virology, 357, pp.186~198 (2007)
- Dudek TE, "Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa", J Infect Dis, 203, pp.1434~1441 (2011)
- Bourne N, "Herpes simplex virus(HSV)type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs", J Infect Dis, 187, pp.542~549 (2003)
- Stanberry LR, "Glycoprotein-D-adjuvant vaccine to prevent genital herpes", N Engl J Med, 347, pp.1652~1661 (2002)
- Belshe RB, "Efficacy results of a trial of a herpes simplex vaccine", N Engl J Med, 366, pp.34~43 (2012)
- Awasthi S, "Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine", Vaccine, 27, pp.6845~6853 (2009)
- Liu BL, "5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties", Gene Ther, 10, pp.292~303 (2003)
- Gyotoku T, "Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK", Vaccine, 20, pp.2796~2807 (2002)
- de Bruyn G, "A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects", Vaccine, 24, pp.914~920 (2006)
- Davidson AH, "Immunologic responses to West Nile virus in vaccinated and clinically affected horses", J Am Vet Med Assoc, 226, pp.240~245 (2005)
- Sin J, "DNA vaccines encoding interleukin-8 and RANTES enhance antigenspecific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo", J Virol, 74, pp.11173~11180 (2000)
- Kim TW, "Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigenspecific CD8-positive memory T cells and protective immunity", Hum Gene Ther, 15, pp.167~177 (2004)
- Tengvall S, "Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2protein vaccination against genital herpes", J Virol, 80, pp.5283~5291 (2006)